行情

INO

INO

Inovio制药
NASDAQ

实时行情|Nasdaq Last Sale

2.510
-0.180
-6.69%
已收盘, 16:00 09/17 EDT
开盘
2.700
昨收
2.690
最高
2.726
最低
2.430
成交量
52.10万
成交额
--
52周最高
6.30
52周最低
2.030
市值
2.49亿
市盈率(TTM)
-2.0694
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

INO 新闻

  • Odds Not In Our Favor With Inovio Pharmaceuticals
  • Seeking Alpha - Article.14小时前
  • Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection
  • PR Newswire.20小时前
  • Inovio Reports Received $4.6M NIH Funding To Target dMAb Technology Against Antimicrobial-Resistant Infection
  • Benzinga.21小时前
  • Inovio Pharmaceuticals, Inc. (INO) Management Presents at H.C. Wainwright 21st Annual Global Investment Conference Transcript
  • Seeking Alpha - Transcript.09/09 20:26

更多

所属板块

生物技术和医学研究
+0.26%
制药与医学研究
+0.57%

热门股票

名称
价格
涨跌幅

INO 简况

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
展开

Webull提供Inovio Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。